Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib

Trial Profile

Phase I Dose Escalation of the MET Inhibitor XL184 and the BRAF Inhibitor Vemurafenib

Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Oct 2014

At a glance

  • Drugs Cabozantinib (Primary) ; Vemurafenib
  • Indications Malignant melanoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 Sep 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 01 Jul 2014 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top